

Form PTO-14

U.S. Department of  
Patent and Trademark OfficeAtty. Docket No.  
575-55873-C/  
JPW/AJM/AABSerial No.  
10/666,513Applicant(s)  
Ann Marie Schmidt, et al.**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)Filing Date  
September 19, 2003

Group Art Unit

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
<i>AM</i>	5 6 8 8 6 5 3	11/18/97	Ulrich, et al.	-	-	
	5 8 6 4 0 1 8	1/26/99	Morser, et al.	-	-	
	5 9 7 6 8 3 2	11/2/99	Hitomi, et al.	-	-	

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<i>AM</i>	WO	9 7 3 9 1 2 1	10/23/97	PCT	-	-		
	WO	9 7 3 9 1 2 5	10/23/97	PCT	-	-		

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**


<i>AM</i>	Baynes, J. W. (1991). Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412;
	Borchelt, D. R., et al. (1996). Familial Alzheimer's Disease-linked presenilin 1 variants elevate A $\beta$ 1-42/1-40 ratio <i>in vitro</i> and <i>in vivo</i> . Neuron 17: 1005-1013;
	Brett, J., et al. (1993). Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 143(6):1699-1712;
	Brownlee, M. (1992). Glycation products and the pathogenesis of diabetic complications. Diabetes Care 15(12):1835-1842;
	Cai, X-D., et al. (1993). Release of excess amyloid $\beta$ protein from a mutant amyloid $\beta$ protein precursor. Science 259: 514-516;
	Citron, M., et al. (1997). Mutant presenilins of Alzheimer's Disease increase production of 42-residue amyloid $\beta$ -protein in both transfected cells and transgenic mice. Nature Medicine 3(1): 67-72;

EXAMINER

DATE CONSIDERED

-8.19.04

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
575-55873-C/  
JPW/AJM/AABSerial No.  
10/666,513**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)Applicant(s)  
Ann Marie Schmidt, et al.Filing Date  
September 19, 2003

Group Art Unit

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No


**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

Am	Dell'Angelica, E.C., et al. (1994). Primary structure and binding properties of calgranulin C, a novel S100-like calcium-binding protein from pig granulocytes. J. Biol. Chem. 269: 28929-28936;
	Fahey, T., et al. (1991). Diabetes impairs the late inflammatory response to wound healing. J. Surg. Res. 50: 308-313;
	Fu, M-X., et al. (1996). The advanced glycation end product, N <sup>ε</sup> -(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J. Biol. Chem. 271: 9982-9986;
	Giardino, I., et al. (1994). Nonenzymatic glycosylation <i>in vitro</i> and in bovine endothelial cells alters basic fibroblast growth factor activity. J. Clin. Invest. 94: 110-117;
	Gibbons, G. H. and V. J. Dzau. (1996). Molecular therapies for vascular diseases. Science 272: 689-693.;
	Hofmann, M. A., et al. (1999). RAGE mediates a novel proinflammatory axis: a central cell surface receptor for s100/calgranulin polypeptides. Cell 97:889-901;

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
575-55873-C/  
JPW/AJM/AABSerial No.  
10/666,513Applicant(s)  
Ann Marie Schmidt, et al.Filing Date  
September 19, 2003

Group Art Unit

**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

AN	Hori, O., et al. (1995). The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin J. Biol. Chem. 270: 25752-25761;
	Khoury, J. E., et al., (1994). Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors. J. Biol. Chem. 269: 10197-10200;
	Kuo, Y-M., et al. (1996). Water-soluble A $\beta$ (N-40, N-42) oligomers in normal and Alzheimer Disease brains. J. Biol. Chem. 271(8): 4077-4081;
	Lander, H. M., et al. (1997). Activation of the receptor for advanced glycation end products triggers a p21 <sup>ras</sup> dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 272: 17810-17814;
	Ledesma, M. D., et al. (1994). Analysis of microtubule-associated protein tau glycation in paired helical filaments. J. Biol. Chem. 269(34):21614-21619;

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.





Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
575-55873-C/  
JPW/AJM/AABSerial No.  
10/666,513Applicant(s)  
Ann Marie Schmidt, et al.Filing Date  
September 19, 2003

Group Art Unit

**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	Nakamura, Y., et al. (1993). Immunohistochemical localization of advanced glycosylation endproducts in coronary atheroma and cardiac tissue in diabetes mellitus. Am. J. Pathol. 143(6): 1649-1656;
	Neeper, M., et al. (1992). Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267: 14998-15004;
	Palinski, W., et al. (1995). Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscl. Thromb. and Vasc. Biol. 15(5): 571-582;
	Park, L., et al. (1998). Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nature Medicine 4: 1025-1031;
	Park, L., et al. (1997). A murine model of accelerated diabetic atherosclerosis: suppression by soluble receptor for advanced glycation endproducts. Circulation Supplement. Abstract 3079;

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
575-55873-C/  
JPW/AJM/AABSerial No.  
10/666,513Applicant(s)  
Ann Marie Schmidt, et al.Filing Date  
September 19, 2003

Group Art Unit

**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No


**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	Reddy, S., et al. (1995). N <sup>c</sup> -(Carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34: 10872-10878;
	Rénard, C., et al. (1997). Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol. Pharm. 52: 54-62;
	Ritthaler, U., et al. (1995). Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease, Am. J. Pathol. 146: 688-694;
	Roher, A. E., et al. (1996). Morphology and toxicity of A $\beta$ -(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's Disease. J. Biol. Chem. 271(34): 20631-20635;
	Schleicher, E. D., et al. (1997). Increased accumulation of the glycooxidation product N <sup>c</sup> -(carboxymethyl)lysine in human tissues in diabetes and aging. J. Clin. Invest. 99: 457-468;

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
575-55873-C/  
JPW/AJM/AABSerial No.  
10/666,513**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)Applicant(s)  
Ann Marie Schmidt, et al.Filing Date  
September 19, 2003

Group Art Unit

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	Schmidt, A. M., et al. (1995). Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. J. Clin. Invest. 96: 1395-1403;
	Schmidt, A. M., et al. (1994). Receptor for advanced glycation endproducts (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc. Nat'l Acad. Sci. USA 91: 8807-8811;
	Schmidt, A. M., et al. (1992). Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 267: 14987-14997;
	Schmidt, A. M., et al. (1994). Cellular receptors for advanced glycation end products. Arterioscler. Thromb. 14:1521-1528;
	Schmidt, A. M., et al. (1995). The dark side of glucose. (News and Views). Nature Medicine 1: 1002-1004;

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
575-55873-C/  
JPW/AJM/AABSerial No.  
10/666,513**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)Applicant(s)  
Ann Marie Schmidt, et al.Filing Date  
September 19, 2003

Group Art Unit

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	Schmidt, A. M., et al. (1993). Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J. Clin. Invest. 92: 2155-2168;
	Schmidt, A. M., et al. (1997). The V-domain of receptor for advanced glycation endproducts (RAGE) mediates binding of AGEs: a novel target for therapy of diabetic complications. Circulation Supplement 96:#194, p. I-37;
	Schmidt, A. M., et al. (1994). The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. J. Biol. Chem. 269: 9882-9888;
	Schmidt, A.M., et al. (1998). RAGE: a receptor with a taste for multiple ligands and varied pathophysiologic states. Hormones and Signaling 1:41-63;
	Sell, D., et al. (1989). Structure elucidation of a senescence cross-link from human extracellular matrix; implication of pentoses in the aging process. J. Biol. Chem. 264:21597-21602;


EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



[illegible]



Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
575-55873-C/  
JPW/AJM/AABSerial No.  
10/666,513Applicant(s)  
Ann Marie Schmidt, et al.Filing Date  
September 19, 2003

Group Art Unit

**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	Vlassara, H., et al. (1995). Identification of Galectin-3 as a high affinity binding protein for advanced glycation end products. Arterioscler. Thromb. 14:1521-1528;
	Wautier, J.-L., et al. (1996). Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Invest. 97: 238-243;
	Wautier, J.-L., et al. (1996). Interaction of diabetic erythrocytes bearing advanced glycation endproducts with the endothelial receptor AGE induces generation of reactive oxygen intermediates and cellular dysfunction. Circulation Supplement 94(8): #4139;
	Wu J., et al. (1997). The soluble receptor for advanced glycation endproducts (sRAGE) ameliorates impaired wound healing in diabetic mice. Plastic Surg. Res. Council Abstract #77, p. 43;

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
575-55873-C/  
JPW/AJM/AABSerial No.  
10/666,513

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Applicant(s)  
Ann Marie Schmidt, et al.Filing Date  
September 19, 2003

Group Art Unit



## U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Yan, S. D., et al. (1994). Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem. 269: 9889-9897;
	Yan, S. D., et al. (1996). RAGE and amyloid- $\beta$ peptide neurotoxicity in Alzheimer's disease. Nature 382: 685-691;
	Yan, S. D., et al. (1997). Amyloid- $\beta$ peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc. Nat'l Acad. Sci. 94: 5296-5301;

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.